Comparative Pharmacology
Head-to-head clinical analysis: POHERDY versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POHERDY versus SERNIVO.
POHERDY vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
POHERDY: No approved drug. No dosing available.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid